title: Clinical economics review: Helicobacter pylori-associated peptic ulcer disease.
abstract: The high prevalence and chronic nature of peptic ulcer disease have traditionally resulted in a major economic burden on health care systems. In 1991, for example, peptic ulcer disease was estimated to account for over one-third of all National Health Service expenditure on gastrointestinal diseases. It is now well established that elimination of Helicobacter pylori can lead to a dramatic reduction in gastroduodenal ulcer relapse, with obvious clinical benefits. This review considers the economic implications of the use of H. pylori eradication therapy in peptic ulcer disease.
authors.affiliation: Division of Medicine, St James's University Hospital, Leeds, UK.
authors.forename: K
authors.initials: K
authors.lastname: Bodger
authors.forename: M J
authors.initials: MJ
authors.lastname: Daly
authors.forename: R V
authors.initials: RV
authors.lastname: Heatley
mesh_terms: D002986:Clinical Trials as Topic; D003362:Cost-Benefit Analysis; D019468:Disease Management; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D016480:Helicobacter pylori; D006801:Humans; D010437:Peptic Ulcer / Q000188:drug therapy / Q000191:economics* / Q000382:microbiology